Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 3,993 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 3,993 shares of Maze Therapeutics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $26.00, for a total transaction of $103,818.00. Following the sale, the chief executive officer directly owned 25,930 shares of the company’s stock, valued at $674,180. This represents a 13.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 0.7%

Shares of NASDAQ:MAZE traded up $0.19 during midday trading on Wednesday, hitting $26.60. The company had a trading volume of 657,539 shares, compared to its average volume of 688,291. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 12 month low of $9.83 and a 12 month high of $53.65. The firm has a fifty day simple moving average of $25.67 and a 200 day simple moving average of $36.25. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -10.51 and a beta of 2.27.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. On average, analysts predict that Maze Therapeutics, Inc. will post -2.76 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MAZE. HC Wainwright increased their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Guggenheim upped their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its stake in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $43,000. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.